News
01-06-2009, 08:20 PM
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX ) today announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.
More... (http://www.news-medical.net/?id=44736)
More... (http://www.news-medical.net/?id=44736)